These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27982762)

  • 1. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
    J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
    Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
    Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case.
    Snyder MH; Ampie L; DiDomenico JD; Asthagiri AR
    J Clin Neurosci; 2021 Apr; 86():79-84. PubMed ID: 33775351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab.
    Essayed WI; Bernard A; Kalamarides M
    J Neurooncol; 2015 Nov; 125(2):445-6. PubMed ID: 26337624
    [No Abstract]   [Full Text] [Related]  

  • 5. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
    Plotkin SR; O'Donnell CC; Curry WT; Bove CM; MacCollin M; Nunes FP
    J Neurosurg Spine; 2011 Apr; 14(4):543-7. PubMed ID: 21294614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal ependymomas in NF2: a surgical disease?
    Kalamarides M; Essayed W; Lejeune JP; Aboukais R; Sterkers O; Bernardeschi D; Peyre M; Lloyd SK; Freeman S; Hammerbeck-Ward C; Kellett M; Rutherford SA; Evans DG; Pathmanaban O; King AT
    J Neurooncol; 2018 Feb; 136(3):605-611. PubMed ID: 29188529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
    Hagel C; Stemmer-Rachamimov AO; Bornemann A; Schuhmann M; Nagel C; Huson S; Evans DG; Plotkin S; Matthies C; Kluwe L; Mautner VF
    Neuropathology; 2012 Dec; 32(6):611-6. PubMed ID: 22394059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.
    Ebert C; von Haken M; Meyer-Puttlitz B; Wiestler OD; Reifenberger G; Pietsch T; von Deimling A
    Am J Pathol; 1999 Aug; 155(2):627-32. PubMed ID: 10433955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurofibromatosis type 2].
    Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
    Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas.
    Lamszus K; Lachenmayer L; Heinemann U; Kluwe L; Finckh U; Höppner W; Stavrou D; Fillbrandt R; Westphal M
    Int J Cancer; 2001 Mar; 91(6):803-8. PubMed ID: 11275983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is NF2 a Key Player of the Differentially Expressed Gene Between Spinal Cord Ependymoma and Intracranial Ependymoma?
    Kim KT; Lee CH; Chung CK; Kim JH
    World Neurosurg; 2018 Oct; 118():e906-e917. PubMed ID: 30031196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.
    Kuga Y; Ohnishi H; Kodama Y; Takakura S; Hayashi M; Yagi R; Fukutome K; Matsushima K; Okamoto K; Taomoto K; Takahashi H
    Neuropathology; 2014 Aug; 34(4):406-13. PubMed ID: 24612193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN immunohistochemistry as surrogate marker for MYCN-amplified spinal ependymomas.
    Mohan D; Nambirajan A; Malik R; Sharma A; Suri V; Kaur K; Doddamani R; Garg A; Gupta S; Mallick S; Sharma MC
    Hum Cell; 2024 May; 37(3):704-713. PubMed ID: 38411836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.